



# IDEAYA Biosciences

Improving Lives  
Through Transformative  
Precision Medicines

NASDAQ: **IDYA**  
September 2022

## IDEAYA Highlights

**Breakthrough Science** on transformative programs in Synthetic Lethality – an emerging area of precision medicine

**Broad Pipeline** of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

**Proven Management Team** with deep business and scientific experience has built leading oncology companies

**Pharma Strategic Partnerships** with GlaxoSmithKline<sup>1</sup>, including ~\$2 billion in potential cash milestones, Pfizer<sup>2</sup> and Amgen<sup>3</sup>

**Strong Balance Sheet** of ~\$419 million<sup>4</sup> with capital efficient model, anticipated to fund operations into 2025

**Analyst Coverage** by JP Morgan, Guggenheim, Jefferies, Oppenheimer, RW Baird, Stifel and Wedbush

(1) GSK Collaboration, Option and License Agreement ; (2) Pfizer Clinical Trial Collaboration and Supply Agreements; (3) Amgen Clinical Trial Collaboration and Supply Agreement; (4)) Includes aggregate of ~\$323.8M cash, cash equivalents and marketable securities as of June 30, 2022, plus pro forma estimated aggregate proceeds from (1) follow-on public offering as of closing September 19, 2022 (\$86.5M, net of underwriter fees) and (2) sales of common stock under the at-the-market offering from July 1, 2022 through September 13, 2022 (\$9.0M ATM, net of sales agent fees)